ABSTRACT
PURPOSE:
To characterize a commonly occurring increased uptake by the uncinate process of the pancreas at PET/CT using 68Ga-DOTA-d-Phe1-Tyr3-octreotide (68Ga-DOTA-TOC). This tracer has replaced In pentetreotide (OctreoScan®) for somatostatin receptor scintigraphy at our laboratory.
METHODS:
Fifty of our first 74 PET/CT examinations with 68Ga-DOTA-TOC could be evaluated in retrospect. None of these patients had surgery or showed any pathology in the pancreas head at the concomitant CT.
RESULTS:
Thirty-five of the 50 examinations (70%) showed an uptake by the uncinate process sufficiently intense to be interpreted as pathologic and simulating a tumor. Mean SUVmax was 9.2. Mean SUVmean using an isoactivity cut-off of >75% and >50% was 7.8 and 6.0, respectively. Volume calculations of the uncinate process activity using these definitions gave 0.9 mL and 4.2 mL, respectively.
CONCLUSION:
There is a frequent physiological uptake of 68Ga-DOTA-TOC by the pancreas uncinate process. This may be caused by an accumulation of pancreatic polypeptide-containing cells expressing somatostatin receptors. If there is a normal finding at concomitant diagnostic CT, this uptake should be regarded as physiological.
Normal uptake of 68Ga-DOTA-TOC by the pancreas uncinate process mimicking malignancy at somatostatin receptor PET.
Riferimento:
Clin Nucl Med. 2012 Apr;37(4):362-5.
Autori:
Jacobsson H, Larsson P, Jonsson C, Jussing E, Grybäck P.
Fonte:
Clin Nucl Med. 2012 Apr;37(4):362-5.
Anno:
2012
Azione:
C'è una captazione fisiologica frequente di 68Ga-DOTATOC da parte del processo uncinato del pancreas. Ciò può essere causato da un accumulo di cellule contenenti polipeptidi pancreatici che esprimono recettori per la somatostatina.
Target:
68Ga-DOTATOC/processo uncinato del pancreas.
Sostanze: